Revisiting In re Cellect: Strategy Adjustments and the Narrowing Impact of Allergan USA v. MSN Labs (RECORDING)

Paul Berghoff, founder of McDonnell Boehnen Hulbert Berghoff LLP, has three decades of experience as lead trial counsel in complex patent litigation – both jury and bench trials and PTAB proceedings – concentrating in litigation involving pharmaceuticals, medical devices, biotechnology, electronics, and software. He has successfully tried scores of patent cases and has successfully argued dozens of times before he US Court of Appeals for the Federal Circuit. He services as Chair of the firm’s Litigation & Appeals Practice Group. He is Vice-Chair of IPO’s Amicus Brief Committee.

Gary J. Gershik specializes in global patent procurement and enforcement, serving a range of clients from academic institutions to Fortune 500 companies. His expertise spans biotechnology, chemistry, and pharmaceuticals. He manages intellectual property and regulatory strategies, provides opinions on patentability and infringement, and has extensive experience in drafting and prosecuting patents domestically and internationally. Gary also handles litigation in U.S. Federal Courts and administrative proceedings before the U.S. Patent and Trademark Office, including Inter-Partes Review (IPR) and Post-Grant Review (PGR), as well as international patent offices. 

Jennifer (Jen) Richie is an intellectual property attorney at Leydig, Voit & Mayer, Ltd. Jen’s practice focuses on patent prosecution, due diligence, and intellectual property transactions. Her technical areas in patent prosecution include biotechnology, biomedical compositions and devices, and the chemical arts.